Grant of Options

19 April 2021

Instem plc
("Instem" or the "Company" or the "Group")

Grant of Options

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have been granted awards of nil-cost options over 4,387 and 3,031 ordinary shares of 10 pence each (“Ordinary Shares”) respectively under the Instem plc 2018 Long Term Incentive Plan ("LTIP").  These options will ordinarily vest and become exercisable on 1 January 2024 pursuant to the rules of the LTIP, conditional upon the individual being in employment with the Group at the date of vesting.

After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 183,816 and 254,531 Ordinary Shares, respectively.

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Phil Reason
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 10 pence each
GB00B3TQCK30
b) Nature of the transaction Grant of nil cost options under the Company’s LTIP
c) Price(s) and volume(s) Price
Nil
Volume(s)
4,387
d) Aggregated information
- Aggregated volume
- Price
N/A – single transaction
e) Date of the transaction 16 April 2021
f) Place of the transaction Outside a trading venue

 

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Nigel Goldsmith
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 10 pence each
GB00B3TQCK30
b) Nature of the transaction Grant of nil cost options under the Company’s LTIP
c) Price(s) and volume(s) Price
Nil
Volume(s)
3,031
d) Aggregated information
- Aggregated volume
- Price
N/A – single transaction
e) Date of the transaction 16 April 2021
f) Place of the transaction Outside a trading venue

 

For further information, please contact:

Instem plc Via Walbrook
Phil Reason, CEO  
Nigel Goldsmith, CFO  
N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel / Alex Bond  
Rachel Hayes  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8780
Nick Rome instem@walbrookpr.com
Tom Cooper  
Nicholas Johnson  

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit instem.com.